ArticleMedical science monitor basic research2021
Cytotoxicity and Antiplasmodial Properties of Different Hylocereus polyrhizus Peel Extracts.
Article in Medical science monitor basic research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Nutritional Value and Therapeutic Benefits of Dragon Fruit: A Comprehensive Review with Implications for Establishing Australian Industry Standards.Molecules (Basel, Switzerland) · 2024Review
- Altitudinal variation of dragon fruit metabolite profiles as revealed by UPLC-MS/MS-based widely targeted metabolomics analysis.BMC plant biology · 2024Article
- Anti-Inflammatory, Antioxidant, and Other Health Effects of Dragon Fruit and Potential Delivery Systems for Its Bioactive Compounds.Pharmaceutics · 2023Review
- Phytochemical analysis and comprehensive evaluation of pharmacological potential ofSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2022Article
- Free Radical Scavenging, Anti-Infectious, and Toxicity Activities fromAdvances in pharmacological and pharmaceutical sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND Dragon fruit (Hylocereus polyrhizus) is one of the most common fruits in tropical countries, including Indonesia. The unique deep purple-colored pulp of the fruit is eaten whole and consumed as juice. However, the inedible thick peel is wasted, causing environmental issues. In this study, the toxic, cytotoxic, and antiplasmodium activity from various extract of H. polyrhizus peels were examined. MATERIAL AND METHODS We evaluated the cytotoxicity and antiplasmodial properties of the various peel extracts by using different organic solvents.The extraction of the peels was conducted using maceration to obtain pigment, n-hexane, dichloromethane, and ethyl acetate extracts. The toxicity of the extract was assessed using the brine shrimp lethality test, followed by WST assay to test in vitro cytotoxic properties and in vitro antiplasmodial properties in 2 Plasmodium falciparum strains (3D7 and W2). RESULTS The n-hexane, dichloromethane, and ethyl acetate extracts depicted various levels of activity, whereas the pigment extract did not show any activities. However, dichloromethane demonstrated a high toxicity level with LC₅₀ of 10.32±0.13 μg/mL and a weak cytotoxic level against SK-OV-3 cell lines (IC₅₀ of 560.86±0.63 μg/mL). Moreover, the dichloromethane and n-hexane extracts showed high and promising antiplasmodial activity with IC₅₀ 2.13±0.42 and 6.51±0.49 μg/mL, respectively. CONCLUSIONS The dichloromethane extract demonstrated high antiplasmodial activity. Our observations have elucidated the cytotoxic and antiplasmodial activity of the peel of dragon fruits and can be used as a foundation for further research into the isolation and bioactivity of secondary metabolites.
Indexed as
Identifiers
34035208PMC8166650What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.